Kura Oncology (NASDAQ:KURA) Downgraded by Stifel Nicolaus

Stifel Nicolaus lowered shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a research note released on Monday, MarketBeat.com reports. The firm currently has $19.00 price objective on the stock, down from their previous price objective of $26.00.

Several other research analysts also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $29.20.

Kura Oncology Price Performance

NASDAQ:KURA opened at $18.27 on Monday. Kura Oncology has a one year low of $7.41 and a one year high of $24.17. The company has a market cap of $1.39 billion, a P/E ratio of -8.42 and a beta of 0.84. The firm’s fifty day moving average price is $19.56 and its two-hundred day moving average price is $20.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.04. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company earned ($0.53) earnings per share. Equities analysts expect that Kura Oncology will post -2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KURA. Hennion & Walsh Asset Management Inc. grew its position in shares of Kura Oncology by 42.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after buying an additional 54,031 shares during the last quarter. Saxon Interests Inc. acquired a new position in shares of Kura Oncology in the first quarter worth approximately $201,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Kura Oncology by 12.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock valued at $874,000 after acquiring an additional 4,659 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Kura Oncology during the 1st quarter valued at approximately $110,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in Kura Oncology during the 1st quarter worth approximately $507,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.